Unity Biotechnology has expanded its ongoing Phase I trial to evaluate UBX0101 in patients with moderate to severe osteoarthritis (OA) of the knee.

The company has added a new cohort of 24 patients to examine 4mg UBX0101, the highest evaluated dose.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Part B expansion is designed to complement the initial Part A of the trial and will further analyse the impact of UBX0101 on certain pro-inflammatory and extracellular matrix modifying factors within the Senescence-Associated Secretory Phenotype (SASP).

Part B will see Unity collect increased volume of synovial fluid samples from the knee joint of patients for SASP assessment.

The company also aims to carry out the lavage procedure in patients who do not have adequate amount of fluid to collect via simple aspiration.

“Around 24 patients are expected to be enrolled and randomised in a 2:1 ratio to receive 4mg UBX0101 or placebo for Part B.”

The inclusion of Part B is the result of a review of the blinded safety, tolerability and drug exposure data received in Part A, which has completed patient enrolment and at least two-week of assessments of all patients.

Top-line results from both Part A and B are expected in the second quarter of this year.

The Phase I study features a randomised, double-blind, placebo-controlled, single ascending dose design.

It aims to investigate the safety, tolerability, and pharmacokinetics of a single intra-articular injection of UBX0101.

Part A of the trial saw 48 patients randomly distributed in 3:1 ratio to receive either UBX0101 or placebo.

Around 24 patients are expected to be enrolled and randomised in a 2:1 ratio to receive 4mg UBX0101 or placebo for Part B.

Primary objectives of both parts of the trial are safety and tolerability, while the secondary and exploratory objectives include plasma pharmacokinetics, synovitis as assessed by MRI, as well as pain and SASP factors in synovial fluid.